-
前列腺癌是欧美国家男性最常见的恶性肿瘤,也是全球男性继肺癌之后第二大恶性肿瘤[1]。我国前列腺癌的发病率虽低于西方国家,但随着人口老龄化及生活条件的改善,前列腺癌总体发病率也有逐年增高的趋势[2],前列腺癌的诊断和治疗已逐渐成为医学研究的热点。本文对铃蟾肽(bombesin)在前列腺癌的放射性核素受体显像及靶向治疗领域的研究进展进行综述。
放射性核素标记铃蟾肽在前列腺癌诊治中的研究进展
Progress of radiolabelled bombesin in diagnosis and treatment of prostate cancer
-
摘要: 前列腺癌等多种肿瘤细胞表面能过度表达铃蟾肽受体,因此,铃蟾肽及其受体可以作为靶点进行放射性核素受体显像及靶向治疗肿瘤,并成为近年来诊治前列腺癌的研究热点。该文综述了放射性核素标记铃蟾肽在前列腺癌显像及治疗方面的研究进展。Abstract: Studies show that high expression of bombesin exist in the face of many kind of tumors such as prostate cancer, so bombesin and its receptor can be used as target in radionuclide receptor imaging and targeted therapy of tumor, and become the focus of prostate cancer research. This article reviews the progress of radiolabelled bombesin in prostate cancer imaging and therapy.
-
Key words:
- Caerulein /
- Prostatic neoplasms /
- Radionuclide imaging /
- Brachytherapy
-
[1] Jadvar H. Molecular imaging of prostate cancer: a concise synopsis. Mol Imaging, 2009, 8(2): 56-64. [2] 中华医学会泌尿外科分会. 前列腺癌诊断治疗指南. 中华现代外科学杂志, 2006, 3(22): 1839-1856.
[3] Anastasi A, Erspamer V, Bucci M. Isolation and structure of bombesin and alytesin, 2 analogous active peptides from the skin of the European amphibians Bombina and Alytes. Experientia, 1971, 27(2): 166-167. doi: 10.1007/BF02145873 [4] Cornelio DB, Roesler R, Schwartsmann G. Gastrin-releasing pep-tide receptor as a molecular target in experimental anticancer therapy. Ann Oncol, 2007, 18(9): 1457-1466. doi: 10.1093/annonc/mdm058 [5] Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res, 1999, 59(5): 1152-1159. [6] Stangelberger A, Schally AV, Djavan B. New treatment approaches for prostate cancer based on peptide analogues. Eur Urol, 2008, 53(5): 890-900. doi: 10.1016/j.eururo.2007.12.021 [7] Schroeder RP, van Weerden WM, Bangma C, et al. Peptide receptor imaging of prostate cancer with radiolabelled bombesin analogues. Methods, 2009, 48(2): 200-204. doi: 10.1016/j.ymeth.2009.04.002 [8] Yang YS, Zhang X, Xiong Z, et al. Comparative in vitro and in vivo evaluation of two 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma. Nucl Med Biol, 2006, 33(3): 371-380. doi: 10.1016/j.nucmedbio.2005.12.011 [9] Duncan JR, Stephenson MT, Wu HP, et al. Indium-111-diethylene-triaminepentaacetic acid-octreotide is delivered in vivo to pancre-atic, tumor cell, renal, and hepatocyte lysosomes. Cancer Res, 1997, 57(4): 659-671. [10] Maecke HR, Hofmann M, Haberkorn U. (68)Ga-labeled peptides in tumor imaging. J Nucl Med, 2005, 46 (Suppl 1): 172S-178S. [11] Maina T, Nock B, Mather S. Targeting prostate cancer with radiola-belled bombesins. Cancer Imaging, 2006, 6: 153-157. doi: 10.1102/1470-7330.2006.0025 [12] Zhang X, Cai W, Cao F, et al. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. J Nucl Med, 2006, 47(3): 492-501. [13] Chen X, Park R, Hou Y, et al. Micro PET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts. J Nucl Med, 2004, 45(8): 1390-1397. [14] Lantry LE, Cappelletti E, Maddalena ME, et al. 177Lu-AMBA: syn-thesis and characterization of a selective 177Lu-labeled GRP-R ago-nist for systemic radiotherapy of prostate cancer. J Nucl Med, 2006, 47(7): 1144-1152. [15] Johnson CV, Shelton T, Smith CJ, et al. Evaluation of combined (177)Lu-DOTA-8-AOC-BBN(7-14)NH(2) GRP receptor-targeted radiotherapy and chemotherapy in PC-3 human prostate tumor cell xenografted SCID mice. Cancer Biother Radiopharm, 2006, 21(2): 155-166. doi: 10.1089/cbr.2006.21.155
计量
- 文章访问数: 977
- HTML全文浏览量: 445
- PDF下载量: 1